- Home
- GIGM vs PLUR Comparison
GIGM vs PLUR Comparison
Compare GIGM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | PLUR |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 12.5M |
| IPO Year | 2002 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GIGM | PLUR |
|---|---|---|
| Price | $1.38 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 52.2K |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $0.85 |
| 52 Week High | $1.66 | $4.87 |
Technical Indicators
Market Signals| Indicator | GIGM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 60.59 |
| Support Level | $1.29 | $0.88 |
| Resistance Level | $1.50 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 69.57 | 63.79 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.